• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D/A filed by Selecta Biosciences Inc. (Amendment)

    12/4/23 4:39:22 PM ET
    $SELB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SELB alert in real time by email
    SEC FORM D/A

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001453687
    SELECTA BIOSCIENCES INC
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Cartesian Therapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Cartesian Therapeutics, Inc.
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Gaithersburg MASSACHUSETTS 20878 617-923-1400

    3. Related Persons

    Last Name First Name Middle Name
    Brunn Carsten
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Davis Blaine
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cox Carrie S.
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Barabe Timothy
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    De Silva Nishan
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kalayoglu Murat
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sallin Aymeric S.
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Singer Michael
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Springer Timothy
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Zenner Patrick S.
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kurtoglu Metin
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Miljkovic Milos
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Jewell Chris
    Street Address 1 Street Address 2
    704 Quince Ochard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

       New Notice Date of First Sale 2023-11-13    First Sale Yet to Occur
    X Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    convertible preferred stock convertible into common stock

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
    X Yes    No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $60,250,000 USD
    or    Indefinite
    Total Amount Sold $60,250,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    2

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Cartesian Therapeutics, Inc. /s/ Blaine Davis Blaine Davis Chief Financial Officer 2023-12-04

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $SELB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SELB

    DatePrice TargetRatingAnalyst
    8/18/2023$1.00Outperform → Market Perform
    SVB Securities
    6/14/2022$6.00 → $5.00Buy
    Needham
    6/6/2022$7.00Outperform
    SVB Leerink
    11/1/2021$6.00 → $7.00Buy
    Needham
    More analyst ratings

    $SELB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

      Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last infusion Phase 2 study of Descartes-08 in systemic lupus erythematosus expected to initiate in 1H24 Clinical pipeline expanded following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118M pro forma cash and cash equivalents as of D

      1/8/24 7:10:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

      Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therap

      1/8/24 7:00:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Announces Merger with Cartesian Therapeutics

      – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

      11/13/23 8:05:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Singer Michael was granted 178,000 units of Common Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:12:27 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Davis Blaine was granted 2,424,000 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jewell Christopher M was granted 778,200 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:06 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/14/24 12:38:55 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/9/24 5:13:58 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Selecta Biosciences Inc.

      SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/9/24 8:50:19 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Leadership Updates

    Live Leadership Updates

    See more
    • Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

      WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022. "Blaine is a highly accomplished biopharmaceutical executive with proven financial and business development expertise," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "We are preparing for a number of key potential milestones across our pipeline

      11/28/22 8:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Surface Oncology Appoints Carsten Brunn to Board of Directors

      CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. "I am thrilled to welcome Carsten to the Surface Oncology board," said Rob Ross, M.D., chief executive officer at Surface. "Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we ad

      6/29/22 7:00:00 AM ET
      $SELB
      $SURF
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer

      WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer. "Kevin's deep financial expertise and experience in the gene therapy and rare disease landscape makes him an ideal fit for Selecta's executive team," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "This is an exciting time for Selecta on the heels of our recent collaboration with Cyrus Biotechnology to unlock a new generation of inno

      9/20/21 8:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Selecta Biosciences downgraded by SVB Securities with a new price target

      SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00

      8/18/23 7:37:44 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Selecta Biosciences with a new price target

      Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $5.00 from $6.00 previously

      6/14/22 7:48:06 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Selecta Biosciences with a new price target

      SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00

      6/6/22 7:48:05 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Selecta Biosciences Inc.

      DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 5:27:24 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Selecta Biosciences Inc.

      DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 4:42:00 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Selecta Biosciences Inc.

      PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      1/31/24 4:30:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Financials

    Live finance-specific insights

    See more
    • Selecta Biosciences Announces Merger with Cartesian Therapeutics

      – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

      11/13/23 8:05:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

      – Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its cli

      8/17/23 7:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

      - Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter

      5/4/23 7:30:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care